FIELD: organic chemistry, medicine, pharmacy.
SUBSTANCE: invention relates to derivatives of benzoxazepine and describes derivative of benzoxazepine of the general formula (I): wherein X represents -CO or -SO2; R1, R2, R3 and R4 are chosen independently from hydrogen atom (H), (C1-C4)-alkyl, (C1-C4)-alkoxy-group, (C1-C4)-alkyloxy-(C1-C4)-alkyl, -CF3, halogen atom, nitro-group, cyano-group, -NR8R9, -NR8COR10 and -CONR8R9; R5, R6 and R7 represent independently hydrogen atom (H) or (C1-C4)-alkyl; R8 and R9 represent independently hydrogen atom (H) or (C1-C4)-alkyl; or R8 and R9 in common with nitrogen atom to which they are bound form 5- or 6-membered saturated heterocyclic ring comprising optionally the additional heteroatom chosen from oxygen atom (O), sulfur atom (S) or the group -NR11; R10 represents (C1-C4)-alkyl; R11 represents (C1-C4)-alkyl; A represents residue of 4-7-membered saturated heterocyclic ring comprising optionally oxygen atom wherein ring is substituted optionally with 1-3 substitutes chosen from (C1-C4)-alkyl, (C1-C4)-alkoxy-, hydroxy-group, halogen atom and oxo-group, or to its pharmaceutically acceptable salt under condition that compounds of the formula (I) are excluded wherein X represents -CO, and each among R1-R7 represents hydrogen atom (H), and A represents -(CH2)3 or -(CH2)4; compounds of the formula (I) wherein X represents -CO; R1 represents hydrogen atom (H); R2 represents methyl (CH3); each among R3-R7 represents hydrogen atom (H), and A represents -(CH2)3; compounds of the formula (I) wherein X represents -CO; R1 and R2 represent hydrogen atom (H); R3 represents methyl; each among R4-R7 represents hydrogen atom (H), and A represents -(CH2)3; compounds of the formula (I) wherein X represents -CO; each among R1-R3 represents hydrogen atom (H); R4 represents methyl; each among R5-R7 represents hydrogen atom (H), and A represents -(CH2)3, and compounds of the formula (I) wherein X represents -CO; each among R1-R4 represents hydrogen atom (H); R5 represents methyl; R6 and R7 represent hydrogen atom (H), and A represents -(CH2)3. Also, invention describes pharmaceutical compositions comprising indicated derivatives and using these benzoxazepine derivatives in treatment of neurological diseases and psychotic disorders sensitive to enhancing responses mediated by AMPA receptors in the central nervous system. Invention provides preparing new compounds possessing the useful biological properties.
EFFECT: valuable medicinal properties of compounds and pharmaceutical composition.
8 cl, 1 tbl, 31 ex
Title | Year | Author | Number |
---|---|---|---|
(PYRIDO/THIENO)[f]OXAZEPINE-5-ONE DERIVATIVES, PHARMACEUTICAL COMPOSITION BASED ON THE SAME AND METHOD FOR TREATMENT OF NEUROLOGICAL DISEASES OR MENTAL DISORDERS | 2002 |
|
RU2286347C2 |
HETEROARYL COMPOUNDS AS TKB INHIBITORS AND USE THEREOF | 2015 |
|
RU2742122C2 |
DERIVATIVE OF 1-[(INDOLE-3-YL)CARBONYL]PIPERAZINE, PHARMACEUTICAL COMPOSITION BASED ON THEREOF AND ITS USING | 2003 |
|
RU2318821C2 |
BICYCLIC LACTAMS AND METHODS FOR USE THEREOF | 2016 |
|
RU2716136C2 |
PYRROLO-PYRROLE COMPOSITIONS AS ACTIVATORS OF PYRUVATE KINASE (PKR) | 2018 |
|
RU2736217C2 |
TRICYCLIC DIAZEPINE VASOPRESSIN AND OXYTOCIN ANTAGONISTS, METHOD OF THEIR SYNTHESIS, PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT | 1994 |
|
RU2126006C1 |
PYRAZOLOPYRIMIDONE OR PYRROLOTRIAZONE DERIVATIVES, METHOD OF PREPARING SAME AND PHARMACEUTICAL APPLICATIONS THEREOF | 2014 |
|
RU2674977C2 |
NON-STEROIDAL MODULATORS OF PROGESTERONE RECEPTOR | 2003 |
|
RU2309155C2 |
METHOD FOR PREPARING 6-ALKYLIDENEPENEM DERIVATIVES | 2003 |
|
RU2317297C2 |
NOVEL CONDENSED PYRIDINE DERIVATIVES USED AS C-MET TYROSINE KINASE INHIBITORS | 2013 |
|
RU2619130C2 |
Authors
Dates
2006-07-10—Published
2002-06-05—Filed